Medication-Assisted Treatment (MAT): How It Works in Drug Rehab

Medication-Assisted Treatment combines FDA-approved medications with behavioral counseling to treat substance use disorders — particularly opioid and alcohol addiction. It is one of the most evidence-supported approaches in addiction medicine, backed by decades of clinical research and endorsed by the Substance Abuse and Mental Health Services Administration (SAMHSA). Understanding how MAT fits into the broader landscape of drug rehab helps clarify why it is prescribed, what it does inside the body, and when it is — and is not — the right path.

Definition and scope

MAT is not a workaround or a shortcut. It is a clinical protocol in which pharmacological treatment directly addresses the neurochemical disruption caused by long-term substance use, while counseling addresses the behavioral and psychological dimensions of addiction.

The formal definition from SAMHSA describes MAT as "the use of medications, in combination with counseling and behavioral therapies, to provide a 'whole-patient' approach to the treatment of substance use disorders." That phrase — whole-patient — carries real weight. The medications used in MAT do not treat the symptom of craving in isolation; they act on the same receptor systems that addiction has dysregulated.

SAMHSA recognizes MAT for opioid use disorder (OUD) and alcohol use disorder (AUD) as the primary applications. For opioids, the three FDA-approved medications are methadone, buprenorphine, and naltrexone. For alcohol, the approved options include naltrexone, acamprosate, and disulfiram. These are not interchangeable — each operates through a distinct mechanism and suits a different clinical profile.

The scope of need is significant. According to the 2022 National Survey on Drug Use and Health, approximately 48.7 million Americans met the criteria for a substance use disorder that year. Of those with OUD specifically, fewer than 25% received any form of medication-based treatment — a gap that addiction specialists have called the treatment access crisis.

How it works

The mechanics vary by medication, but the underlying logic is consistent: reduce the physiological reward of using, suppress withdrawal, or create an aversive response to use.

Opioid Use Disorder — three distinct mechanisms:

1. Methadone is a full opioid agonist. It binds to opioid receptors fully, preventing withdrawal and reducing cravings without producing the euphoric peak of illicit opioids when taken at the correct dose. It is dispensed daily at federally licensed opioid treatment programs (OTPs).

2. Buprenorphine is a partial agonist, meaning it activates opioid receptors but with a ceiling effect — stimulation tops out at a certain dose, sharply reducing overdose risk. It is often combined with naloxone (sold as Suboxone) to deter injection misuse. Unlike methadone, it can be prescribed by qualified physicians in office-based settings under the Drug Addiction Treatment Act of 2000 (DATA 2000).

3. Naltrexone (sold as Vivitrol in its extended-release injectable form) is an opioid antagonist — it blocks receptors entirely, making opioid use produce no effect. It requires complete detoxification before starting, since it will precipitate immediate withdrawal in anyone still physically dependent.

Alcohol Use Disorder — the contrast is instructive:

Naltrexone for AUD reduces the reward signal from drinking. Acamprosate stabilizes the brain's glutamate system, which alcohol disrupts, easing the long-term discomfort of abstinence. Disulfiram takes a different approach entirely — it causes a physically unpleasant reaction if alcohol is consumed, acting as a pharmacological deterrent rather than a receptor-level intervention.

The behavioral counseling component is not optional decoration. Clinical guidelines from the American Society of Addiction Medicine (ASAM) specify that medication alone does not constitute MAT; the integrated behavioral component is what distinguishes it from pharmaceutical management.

Common scenarios

MAT appears at different points in the recovery process, not just at the acute treatment phase. Three scenarios account for most clinical applications:

• Stabilization during detox: Methadone and buprenorphine are used in medically supervised withdrawal to prevent dangerous acute withdrawal symptoms, particularly in opioid-dependent patients.

• Maintenance treatment: A patient may remain on buprenorphine or methadone for months or years, functioning normally at work and at home while the risk of relapse is biochemically reduced. The National Institute on Drug Abuse (NIDA) notes that longer duration of MAT is associated with better outcomes, and arbitrary time limits on treatment are not clinically justified.

• Relapse prevention after detox: Extended-release naltrexone (Vivitrol) is particularly suited to patients who have already completed detox and want pharmacological support during high-risk early recovery. Knowing how to access these treatment pathways is often the practical obstacle patients face.

Decision boundaries

MAT is not appropriate for every patient, and it is not the only effective approach. The decision involves the substance involved, the severity of dependence, co-occurring mental health conditions, prior treatment history, and patient preference.

Key boundaries to understand:

• MAT for opioid use disorder requires physical detox from opioids before starting naltrexone, but not before starting buprenorphine or methadone.
• MAT is compatible with 12-step and peer support programs, despite historical tension between those communities. ASAM and NIDA both affirm that using prescribed MAT does not constitute "not being in recovery."

The full scope of what drug rehab involves — detox, residential care, outpatient programs, and ongoing support — frames MAT as one important tool rather than the whole picture. It addresses the biology. The rest of treatment addresses everything else.